What is Galmed Pharmaceu's earnings per share (EPS)?

Galmed Pharmaceu (GLMD) reported diluted earnings per share of $2.39 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Galmed Pharmaceu Financials

GLMD

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Galmed Pharmaceu (GLMD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI GLMD FY2025 2026-04-22

Galmed's business mechanic is cash-funded development, supported by periodic equity financing and a balance sheet with limited hard obligations.

From FY2023 through FY2025, operating cash burn stayed near -$6M a year, but financing inflows repeatedly refilled the balance sheet, leaving FY2025 cash at $4.0M instead of letting liquidity erode in line with losses. The important operating clue is that day-to-day continuity has been maintained more by fundraising cadence than by a materially lower cost base.

FY2025 spending remained research-led, with R&D at $4.9M versus SG&A at $3.6M. That mix suggests cash use is still aimed primarily at advancing development work and keeping the public-company platform running, not at supporting a heavy commercial infrastructure.

The balance sheet is mostly liquid: current assets were $18.6M against current liabilities of $2.8M, producing current coverage above 6x. That keeps near-term obligations manageable, but retained losses of -$210.8M show the enterprise has been funded mainly by shareholder capital rather than by operating self-sufficiency.

Financial Health Signals

Financial Profile 33/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Galmed Pharmaceu's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Galmed Pharmaceu carries a low D/E ratio of 0.18, meaning only $0.18 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 98/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 6.55, Galmed Pharmaceu holds $6.55 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Returns

Galmed Pharmaceu generates a -65.3% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -46.0% the prior year.

Piotroski F-Score Weak

1/9

Galmed Pharmaceu passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.61x

For every $1 of reported earnings, Galmed Pharmaceu generates $0.61 in operating cash flow (-$6.3M OCF vs -$10.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$10.3M

YoY-37.1%

Galmed Pharmaceu reported -$10.3M in net income in fiscal year 2025. This represents a decrease of 37.1% from the prior year.

EPS (Diluted)

$2.39

Galmed Pharmaceu earned $2.39 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 70.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$4.0M

YoY-14.3%

5Y CAGR-10.5%

10Y CAGR-0.4%

Galmed Pharmaceu held $4.0M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

Galmed Pharmaceu had 7M shares outstanding in fiscal year 2025. This represents an increase of 297.8% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-65.3%

YoY-19.3pp

5Y CAGR-0.2pp

10Y CAGR-16.0pp

Galmed Pharmaceu's ROE was -65.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 19.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$4.9M

YoY+63.6%

5Y CAGR-28.5%

10Y CAGR-4.4%

Galmed Pharmaceu invested $4.9M in research and development in fiscal year 2025. This represents an increase of 63.6% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

GLMD Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$4.9M+63.6%	$3.0M-16.5%	$3.6M-72.5%	$13.0M-52.3%	$27.2M+4.4%	$26.1M
SG&A Expenses	$3.6M+10.2%	$3.3M-15.9%	$3.9M-15.7%	$4.7M-17.8%	$5.7M+37.1%	$4.1M
Operating Income	N/A	N/A	N/A	N/A	N/A	-$30.2M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	N/A	N/A	N/A	N/A	$0
Net Income	-$10.3M-37.1%	-$7.5M-8.8%	-$6.9M+61.3%	-$17.9M+45.0%	-$32.5M-12.8%	-$28.8M
EPS (Diluted)	$2.39	$8.08	$30.00	$127.80+545.5%	$19.80	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$1.1M+2.6%	$1.1M	N/A	N/A	$738K+38.2%	$534K	N/A
SG&A Expenses	N/A	$1.0M-4.0%	$1.1M	N/A	N/A	$1.3M+85.0%	$688K	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$1.9M+24.2%	-$2.5M-126.0%	-$1.1M	N/A	-$1.9M-71.0%	-$1.1M+12.2%	-$1.3M
EPS (Diluted)	N/A	$0.33-47.6%	$0.63	N/A	N/A	$2.31+40.0%	$1.65	N/A

GLMD Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$18.6M+0.7%	$18.5M+11.3%	$16.6M+0.4%	$16.6M-54.8%	$36.6M-30.1%	$52.4M
Current Assets	$18.6M+15.5%	$16.1M+21.8%	$13.2M-10.1%	$14.7M-59.2%	$36.1M-30.4%	$51.8M
Cash & Equivalents	$4.0M-14.3%	$4.7M+62.6%	$2.9M+41.9%	$2.0M-30.1%	$2.9M-58.5%	$6.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.8M+30.9%	$2.2M-21.0%	$2.8M-12.4%	$3.1M-48.6%	$6.1M-25.8%	$8.2M
Current Liabilities	$2.8M+30.9%	$2.2M-21.0%	$2.8M-11.1%	$3.1M-47.4%	$5.9M-26.6%	$8.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$15.8M-3.3%	$16.3M+17.6%	$13.9M+3.4%	$13.4M-56.0%	$30.5M-30.9%	$44.2M
Retained Earnings	-$210.8M-5.1%	-$200.5M-3.9%	-$193.0M-3.7%	-$186.0M-10.6%	-$168.2M-23.9%	-$135.7M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$18.6M-13.7%	$21.6M-5.9%	$22.9M	N/A	$18.5M	N/A	$13.3M	N/A
Current Assets	$18.6M-5.6%	$19.7M-6.5%	$21.1M	N/A	$16.1M	N/A	$10.1M	N/A
Cash & Equivalents	$4.0M+20.2%	$3.3M-33.2%	$5.0M	N/A	$4.7M	N/A	$1.8M	N/A
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.8M+15.1%	$2.5M+2.1%	$2.4M	N/A	$2.2M	N/A	$1.6M	N/A
Current Liabilities	$2.8M+15.1%	$2.5M+2.1%	$2.4M	N/A	$2.2M	N/A	$1.6M	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$15.8M-17.4%	$19.1M-6.9%	$20.5M+21.6%	$16.9M+3.4%	$16.3M-11.4%	$18.4M+56.4%	$11.8M-7.6%	$12.8M
Retained Earnings	-$210.8M-2.3%	-$206.0M-0.9%	-$204.1M	N/A	-$200.5M	N/A	-$195.3M	N/A

GLMD Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$6.3M-7.4%	-$5.9M+4.2%	-$6.1M+66.8%	-$18.5M+43.8%	-$32.9M-25.1%	-$26.3M
Capital Expenditures	N/A	N/A	N/A	$4K-63.6%	$11K-75.0%	$44K
Free Cash Flow	N/A	N/A	N/A	-$18.5M+43.8%	-$32.9M-25.0%	-$26.3M
Investing Cash Flow	-$3.4M-203.8%	-$1.1M-238.9%	$800K-95.4%	$17.6M+53.2%	$11.5M-30.7%	$16.5M
Financing Cash Flow	$9.0M+2.7%	$8.8M+42.1%	$6.2M+8735.7%	$70K-99.6%	$17.4M+2161.5%	$768K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$1.9M-0.5%	-$1.9M	N/A	N/A	-$1.9M-69.6%	-$1.1M	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$1.4M+47700.0%	-$3K	N/A	N/A	-$2.4M-403.9%	-$486K	N/A	N/A
Financing Cash Flow	$1.2M+311.1%	$289K	N/A	N/A	$448K	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

GLMD Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-65.3%-19.3pp	-46.0%+3.8pp	-49.8%+83.3pp	-133.1%-26.6pp	-106.5%-41.3pp	-65.2%
Return on Assets	-55.3%-14.7pp	-40.6%+0.9pp	-41.6%+66.3pp	-107.9%-19.2pp	-88.7%-33.8pp	-54.9%
Current Ratio	6.55-0.9	7.42+2.6	4.81+0.1	4.76-1.4	6.13-0.3	6.47
Debt-to-Equity	0.18+0.0	0.13-0.1	0.20-0.0	0.23+0.0	0.20+0.0	0.19
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-9.9%+2.3pp	-12.2%-5.6pp	-6.5%	N/A	-10.4%-0.9pp	-9.5%+0.5pp	-10.0%
Return on Assets	N/A	-8.8%+2.1pp	-10.9%	N/A	N/A	N/A	-8.4%	N/A
Current Ratio	6.55-1.4	7.98-0.7	8.71	N/A	7.42	N/A	6.48	N/A
Debt-to-Equity	0.18+0.1	0.13+0.0	0.12	N/A	0.13	N/A	0.13	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Cyclerion Therapeutics Inc CYCN

$13.5M

Dogwood Therapeutics DWTX

$61.1M

Aprea Therapeutics, Inc. APRE

$11.5M

Vyne Therapeutics Inc VYNE

$22.3M

Frequently Asked Questions

Is Galmed Pharmaceu profitable?

No, Galmed Pharmaceu (GLMD) reported a net income of -$10.3M in fiscal year 2025.

What is Galmed Pharmaceu's return on equity (ROE)?

Galmed Pharmaceu (GLMD) has a return on equity of -65.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Galmed Pharmaceu's operating cash flow?

Galmed Pharmaceu (GLMD) generated -$6.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Galmed Pharmaceu's total assets?

Galmed Pharmaceu (GLMD) had $18.6M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Galmed Pharmaceu spend on research and development?

Galmed Pharmaceu (GLMD) invested $4.9M in research and development during fiscal year 2025.

How many shares does Galmed Pharmaceu have outstanding?

Galmed Pharmaceu (GLMD) had 7M shares outstanding as of fiscal year 2025.

What is Galmed Pharmaceu's current ratio?

Galmed Pharmaceu (GLMD) had a current ratio of 6.55 as of fiscal year 2025, which is generally considered healthy.

What is Galmed Pharmaceu's debt-to-equity ratio?

Galmed Pharmaceu (GLMD) had a debt-to-equity ratio of 0.18 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Galmed Pharmaceu's return on assets (ROA)?

Galmed Pharmaceu (GLMD) had a return on assets of -55.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Galmed Pharmaceu's cash runway?

Based on fiscal year 2025 data, Galmed Pharmaceu (GLMD) had $4.0M in cash against an annual operating cash burn of $6.3M. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Galmed Pharmaceu's Piotroski F-Score?

Galmed Pharmaceu (GLMD) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Galmed Pharmaceu's earnings high quality?

Galmed Pharmaceu (GLMD) has an earnings quality ratio of 0.61x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Galmed Pharmaceu?

Galmed Pharmaceu (GLMD) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.